T1	PrimaryOutcome 21 91	Negative conversion of severe acute respiratory syndrome coronavirus 2
T2	TimeFrame 92 102	by 28 days
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	PrimaryOutcome 573 593	clinical improvement
T4	TimeFrame 594 604	by 28 days
R2	MeasuredAt Arg1:T3 Arg2:T4	
T5	OtherOutcome 160 174	Adverse events
T6	OutcomeDefinition 802 959	two consecutive reports of a negative result for SARS-CoV-2 at least 24 hours apart without a subsequent report of a positive result by the end of the study.
R3	DefinedAs Arg1:T1 Arg2:T6	
T7	SecondaryOutcome 1629 1663	Probability of negative conversion
T9	SecondaryOutcome 2231 2280	probabilities of alleviation of clinical symptoms
T10	SecondaryOutcome 2282 2315	improvement of C reactive protein
T11	SecondaryOutcome 2317 2347	erythrocyte sedimentation rate
T12	SecondaryOutcome 2349 2373	tumour necrosis factor α
T13	SecondaryOutcome 2375 2388	interleukin 6
T14	SecondaryOutcome 2394 2425	absolute blood lymphocyte count
T15	SecondaryOutcome 2427 2473	improvement of lung lesions on chest radiology
T16	SecondaryOutcome 2475 2490	all cause death
T17	SecondaryOutcome 2496 2557	disease progression in patients with mild to moderate disease
T18	TimeFrame 2607 2636	from randomisation to 28 days
R4	MeasuredAt Arg1:T9 Arg2:T18	
R5	MeasuredAt Arg1:T10 Arg2:T18	
R6	MeasuredAt Arg1:T11 Arg2:T18	
R7	MeasuredAt Arg1:T12 Arg2:T18	
R8	MeasuredAt Arg1:T14 Arg2:T18	
R9	MeasuredAt Arg1:T15 Arg2:T18	
R10	MeasuredAt Arg1:T16 Arg2:T18	
R11	MeasuredAt Arg1:T17 Arg2:T18	
T19	OutcomeDefinition 3189 3431	resolving from fever to an axillary temperature of 36.6°C or below, normalisation of SpO2 (>94% on room air), and disappearance of respiratory symptoms including nasal congestion, cough, sore throat, sputum production, and shortness of breath
R12	DefinedAs Arg1:T9 Arg2:T19	
T20	OutcomeDefinition 1876 2115	coded using the latest version of Medical Dictionary for Regulatory Activities coding dictionary, recorded in standard medical terminology and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events
T21	SecondaryOutcome 1861 1875	adverse events
R13	DefinedAs Arg1:T21 Arg2:T20	
T8	PrimaryOutcome 482 515	negative conversion of SARS-CoV-2
T22	TimeFrame 516 526	by 28 days
R14	MeasuredAt Arg1:T8 Arg2:T22	
T23	PrimaryOutcome 1120 1144	Negative conversion rate
T24	TimeFrame 1145 1154	by Day 10
R15	MeasuredAt Arg1:T23 Arg2:T24	
A1	Modification T23 Original
A2	Modification T8 Modified
T25	PrimaryOutcome 1528 1561	negative conversion of SARS-CoV-2
A3	Modification T25 Modified
T26	TimeFrame 1562 1572	by 28 days
R16	MeasuredAt Arg1:T25 Arg2:T26	
A4	Modification T1 Modified
T27	TimeFrame 1664 1690	at day 4, 7, 10, 14, or 21
R17	MeasuredAt Arg1:T7 Arg2:T27	
